Last reviewed · How we verify
Sofosbuvir and simeprevir — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Sofosbuvir and simeprevir (Sofosbuvir and simeprevir) — Arrowhead Regional Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sofosbuvir and simeprevir TARGET | Sofosbuvir and simeprevir | Arrowhead Regional Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sofosbuvir and simeprevir CI watch — RSS
- Sofosbuvir and simeprevir CI watch — Atom
- Sofosbuvir and simeprevir CI watch — JSON
- Sofosbuvir and simeprevir alone — RSS
Cite this brief
Drug Landscape (2026). Sofosbuvir and simeprevir — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-and-simeprevir. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab